BTG International has launched a next-generation treatment option, DC Bead LUMI, for cancer patients in Canada, marking its first worldwide market commercialisation.
Based on the technology platform of the company’s DC Bead, the DC Bead LUMI is a radiopaque embolic drug-eluting bead that can be loaded with the chemotherapy drug doxorubicin to treat hepatocellular carcinoma (HCC), a commonly occurring primary liver cancer.
It can also be loaded with another chemotherapy drug, irinotecan, to treat malignant colorectal cancer metastasised to the liver (mCRC).
Drug-eluting beads are used in trans-arterial chemoembolisation (TACE), a minimally invasive liver cancer treatment that deliberately blocks blood supply to the tumour and locally delivers a controlled, sustained dose of chemotherapy directly to the tumour.
The DC Bead LUMI aids in optimising patient treatment by enabling real-time visible confirmation of bead location during and after the embolisation procedure.
This allows interventional radiologists to have more control simultaneously discovering under-treatment regions, thereby allowing precise evaluation of the completeness of tumour treatment and enhanced end-point determination, with long-lasting radiopacity to support follow-up management.
The treatment option was first performed by Sunnybrook Health Sciences Centre in Canada.
Sunnybrook Health Sciences Centre vascular / interventional radiologist staff Dr Chris Dey said: “The LUMI TACE beads really delivered. They were what one hoped for, so it was easy to see under fluoroscopy, single shot and cone beam CT.
“You can appreciate actual bead deposition in the liver for the first time, flow patterns much more reliably and make intra-procedural adjustments or determine end points more precisely.”